SCHEMBL23037544

SCHEMBL23037544

Cc1cc(N(C)c2ccc3c(c2)c2ccccc2n3Cc2ccccc2)c2ccccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.47
ALDH1A1 P00352 3/20 0.46
TNF P01375 1/20 0.43
P2RX4 Q99571 2/20 0.43
NCF1 P14598 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPK1 P28482 1/20 0.41
TP53 P04637 2/20 0.40
PDE6D O43924 1/20 0.40
ALDH2 P05091 1/20 0.40
ALDH3A1 P30838 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 2/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30060724 1.00 CYP19A1 (0.47) CYP19A1ALDH1A1TNFP2RX4NCF1
SCHEMBL23037532 0.89 MAPT (0.48) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL21883075 0.85 MAPT (0.43) ALDH1A1NCF1MEN1KMT2ASMN1; SMN2
SCHEMBL25992599 0.78 MEN1 (0.46) ALDH1A1NCF1MEN1KMT2ASMN1; SMN2
SCHEMBL23037539 0.77 NCF1 (0.43) ALDH1A1NCF1MEN1KMT2ASMN1; SMN2
SCHEMBL23037565 0.76 PABPC1 (0.43) ALDH1A1NCF1MEN1KMT2AMAPK1
SCHEMBL30367299 0.74 CYP1A2 (0.40) ALDH1A1NCF1MEN1KMT2ASMN1; SMN2
SCHEMBL23037546 0.74 KDM1A (0.47) NCF1
SCHEMBL23037505 0.74 MAPT (0.48) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL17965656 0.74 CYP19A1 (0.66) CYP19A1ALDH1A1P2RX4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371417-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties Universite Paris-Saclay (FR) 2025-07-29 US disclosed
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2023-06-29 US disclosed
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2023-06-29 US disclosed
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2023-06-29 US disclosed
US-11634405-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE (FR) 2023-04-25 US disclosed
US-11634405-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE (FR) 2023-04-25 US disclosed
US-20210230140-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2021-07-29 US disclosed
US-20210230140-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2021-07-29 US disclosed
EP-3784662-A1 COMPOUNDS HAVING A TUBULIN-POLYMERISATION-INHIBITING ACTIVITY AND IMMUNOMODULATORY PROPERTIES Université Paris-Saclay (FR) 2021-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371417-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties TUBB1, TUBB, TUBB3 CYP19A1 4352/4885ALDH1A1 2779/4885TNF 210/4885
US-11634405-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties TUBB1, TUBB, TUBB3 CYP19A1 4352/4885ALDH1A1 2779/4885TNF 210/4885
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES TUBB1, TUBB, TUBB3 CYP19A1 4352/4885ALDH1A1 2779/4885TNF 210/4885
US-20210230140-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES TUBB1, TUBB, TUBB3 CYP19A1 4352/4885ALDH1A1 2779/4885TNF 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.